Trial Profile

A phase 1 study of Obeticholic acid in combination with bezafibrate in USA

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 19 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bezafibrate (Primary) ; Obeticholic acid (Primary)
Indications Primary biliary cirrhosis
Focus Adverse reactions

Most Recent Events

27 Apr 2023 According to Intercept media release, this study will serve as the basis of an end-of-phase II meeting with FDA.
02 Mar 2023 According to an Intercept Pharmaceuticals media release, the company anticipates sharing data from planned analyses later this year.
03 Aug 2022 According to an Intercept Pharmaceuticals media release, Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com